تقرير
أعرض في EDS

Chemotherapy resistant Burkitt lymphoma: Possible novel therapies including CAR-T cell infusion.

التفاصيل البيبلوغرافية
العنوان: Chemotherapy resistant Burkitt lymphoma: Possible novel therapies including CAR-T cell infusion.
المؤلفون: Geerts PAF; Department of Internal Medicine Isala Klinieken Zwolle Netherlands., 't Hart N; Department of Pathology Isala Klinieken Zwolle Netherlands., Visser O; Department of Internal Medicine Isala Klinieken Zwolle Netherlands., Ortiz-Maldonado V; Department of Hematology Hospital Clínic de Barcelona Barcelona Spain., Chamuleau MED; Department of Hematology Amsterdam University Medical Centre Amsterdam Netherlands.
المصدر: Clinical case reports [Clin Case Rep] 2023 May 29; Vol. 11 (6), pp. e7361. Date of Electronic Publication: 2023 May 29 (Print Publication: 2023).
نوع المنشور: Case Reports
اللغة: English
بيانات الدورية: Publisher: John Wiley & Sons Country of Publication: England NLM ID: 101620385 Publication Model: eCollection Cited Medium: Print ISSN: 2050-0904 (Print) Linking ISSN: 20500904 NLM ISO Abbreviation: Clin Case Rep Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Chichester, UK : John Wiley & Sons
مستخلص: Key Clinical Message: The prognosis of patients with relapsed or refractory (R/R) BL is poor with limited response to salvage therapy, especially for patients with early relapse (<6 months) or refractory disease. Novel therapies may be promising but need refinement.
Abstract: The prognosis of patients with relapsed or refractory (R/R) BL is poor with a limited response to salvage therapy, especially for patients with early relapse (<6 months) or refractory disease. We present three cases of patients with R/R BL receiving novel therapies followed by a literature review. Amongst others, the patients received inotuzumab ozogamicin, idelalisib, ibrutinib, and CAR-T cell therapy, however, with limited response. In literature, response to several novel agents is described; however, most promising results are seen with CAR-T cell therapy. Concluding from case series, sequential CAR-T cell therapy, targeting multiple B-cell antigens, seems most promising.
Competing Interests: The authors report no conflicts of interest.
(© 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
References: Blood. 2014 Aug 21;124(8):1259-65. (PMID: 25016003)
Am J Hematol. 2017 Jun;92(6):E114-E117. (PMID: 28295472)
N Engl J Med. 2016 Aug 25;375(8):740-53. (PMID: 27292104)
Oncoimmunology. 2018 Oct 11;8(1):e1512455. (PMID: 30546948)
Biomark Res. 2013 Nov 15;1(1):30. (PMID: 24252186)
Cancers (Basel). 2020 May 28;12(6):. (PMID: 32481736)
Clin Case Rep. 2023 May 29;11(6):e7361. (PMID: 37260617)
J Clin Oncol. 2014 Jan 1;32(1):44-50. (PMID: 24043741)
Leuk Lymphoma. 2006 Aug;47(8):1511-7. (PMID: 16966261)
Leukemia. 2020 Aug;34(8):2271-2275. (PMID: 32071430)
Blood Adv. 2022 Feb 8;6(3):717-730. (PMID: 34521107)
Biol Blood Marrow Transplant. 2013 Feb;19(2):173-9. (PMID: 23200705)
Front Immunol. 2020 Mar 20;11:482. (PMID: 32528460)
Cancer Immunol Immunother. 2021 Aug;70(8):2379-2384. (PMID: 33459843)
Front Oncol. 2019 Feb 18;9:57. (PMID: 30834235)
Nature. 2012 Oct 4;490(7418):116-20. (PMID: 22885699)
Mol Ther. 2021 Feb 3;29(2):636-644. (PMID: 33010231)
Ann Hematol. 2021 Jan;100(1):277-279. (PMID: 32193631)
Leukemia. 2007 Nov;21(11):2240-5. (PMID: 17657218)
J Clin Oncol. 1996 Sep;14(9):2465-72. (PMID: 8823324)
Blood. 2021 Feb 11;137(6):743-750. (PMID: 33171490)
Oncotarget. 2018 Apr 24;9(31):21820-21830. (PMID: 29774105)
Cancer J. 2021 Mar-Apr 01;27(2):107-111. (PMID: 33750069)
فهرسة مساهمة: Keywords: Burkitt lymphoma; cellular therapy; chemotherapy; immunotherapy; targeted therapy
تواريخ الأحداث: Date Created: 20230601 Latest Revision: 20240919
رمز التحديث: 20240919
مُعرف محوري في PubMed: PMC10227197
DOI: 10.1002/ccr3.7361
PMID: 37260617
قاعدة البيانات: MEDLINE
الوصف
تدمد:2050-0904
DOI:10.1002/ccr3.7361